Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in met expression

Journal of Orthopaedic Research

Volumn 28, Issue 6, 2010, Pages 746-752

  Duan, Zhenfeng ^a   Choy, Edwin ^a   Petur Nielsen, G ^a   Rosenberg, Andrew ^a   Iafrate, John ^a   Yang, Cao ^a   Schwab, Joe ^a   Mankin, Henry ^a   Xavier, Ramnik ^a   Hornicek, Francis J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chordoma; Met; miRNA; RT PCR

Indexed keywords

MICRORNA; MICRORNA 1; MIRNA 206; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER TISSUE; CHORDOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION;

CELL LINE, TUMOR; CELL PROLIFERATION; CHORDOMA; GENE EXPRESSION PROFILING; HISTONE DEACETYLASES; HUMANS; MICRORNAS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, GROWTH FACTOR; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77951491894     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21055     Document Type: Article

References (26)

1. Sciubba DM, Chi JH, Rhines LD, et al. 2008. Chordoma of the spinal column. Neurosurg Clin North Am 19:5-15.
2. Chugh R, Tawbi H, Lucas DR, et al. 2007. Chordoma: the nonsarcoma primary bone tumor. Oncologist 12:1344-1350. (Pubitemid 350232608)
3. Muro K, Das S, Raizer JJ. 2007. Chordomas of the craniospinal axis: multimodality surgical, radiation and medical management strategies. Expert Rev Neurother 7:1295-1312. (Pubitemid 350012720)
4. Medina PP, Slack FJ. 2008. MicroRNAs and cancer: an overview. Cell Cycle 7:2485-2492.
5. Shi XB, Tepper CG, deVere White RW. 2008. Cancerous miRNAs and their regulation. Cell Cycle 7:1529-1538.
6. Tong AW, Nemunaitis J. 2008. Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Ther 15:341-355.
7. Iorio MV, Casalini P, Tagliabue E, et al. 2008. MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur J Cancer 44:2753-2759.
8. Marcucci G, Maharry K, Radmacher MD, et al. 2008. Prognostic significance of, and gene and microRNA expression signatures associated with, cebpa mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a cancer and leukemia group b study. J Clin Oncol 26:5078-5087.
9. Schepeler T, Reinert JT, Ostenfeld MS, et al. 2008. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 68:6416-6424.
10. Scheil S, Bruderlein S, Liehr T, et al. 2001. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 32:203-211. (Pubitemid 32953974)
11. Ricci-Vitiani L, Pierconti F, Falchetti ML, et al. 2006. Establishing tumor cell lines from aggressive telomerase-positive chordomas of the skull base. Technical note. J Neurosurg 105:482-484. (Pubitemid 44358765)
12. Duan Z, Foster R, Bell DA, et al. 2006. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 12:5055-5063. (Pubitemid 44453331)
13. Duan Z, Weinstein EJ, Ji D, et al. 2008. Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer. Mol Cancer Ther 7:2377-2385.
14. Kondo N, Toyama T, Sugiura H, et al. 2008. Mir-206 expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res 68:5004-5008.
15. Nasser MW, Datta J, Nuovo G, et al. 2008. Down-regulation of micro-RNA-1 (mir-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by mir-1. J Biol Chem 283:33394-33405.
16. Bartel DP. 2009. MicroRNAs. Target recognition and regulatory functions. Cell 136:215-233.
17. Brandal P, Bjerkehagen B, Danielsen H, et al. 2005. Chromosome 7 abnormalities are common in chordomas. Cancer Genet Cytogenet 160:15-21. (Pubitemid 40798131)
18. Riva P, Crosti F, Orzan F, et al. 2003. Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis. Int J Cancer 107:493-497. (Pubitemid 37266472)
19. Lujambio A, Calin GA, Villanueva A, et al. 2008. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 105:13556-13561.
20. Kozaki K, Imoto I, Mogi S, et al. 2008. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 68:2094-2105. (Pubitemid 351521781)
21. Datta J, Kutay H, Nasser MW, et al. 2008. Methylation mediated silencing of microRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 68:5049-5058.
22. Adams BD, Furneaux H, White BA. 2007. The microribonucleic acid (miRNA) mir-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 21:1132-1147. (Pubitemid 46984764)
23. Phillip CJ, Stellrecht CM, Nimmanapalli R, et al. 2009. Targeting Met transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother Pharmacol 63:587-697.
24. Naka T, Iwamoto Y, Shinohara N, et al. 1997. Expression of c-Met proto-oncogene product (c-Met) in benign and malignant bone tumors. Mod Pathol 10:832-838. (Pubitemid 27374855)
25. Ostroumov E, Hunter CJ. 2008. Identifying mechanisms for therapeutic intervention in chordoma: c-Met oncoprotein. Spine 33:2774-2780.
26. Stellrecht CM, Gandhi V. 2008. Met receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett 280:1-14.